




Healthcare Industry News: GSK
News Release - February 12, 2007
King Pharmaceuticals Appoints Eric G. Carter as Chief Science Officer
BRISTOL, Tenn.--(HSMN NewsFeed)--King Pharmaceuticals, Inc. (NYSE: KG ) announced today the appointment of Eric G. Carter as the Company's Chief Science Officer. Dr. Carter will oversee all of King's research and development, regulatory and medical affairs activities.Dr. Carter joins King with more than 25 years of clinical development and medical affairs experience, including 10 years of senior management experience within the pharmaceutical industry. Most recently, Dr. Carter served as Vice President and Global Head, Clinical Development and Medical Affairs, Gastroenterology, R&D for GlaxoSmithKline ("GSK"). His earlier experience at GSK includes North American responsibility for Gastroenterology and for Emerging therapeutic areas. Prior to GSK, Dr. Carter was employed by Pharmacia & Upjohn as Vice President, Medical and Clinical Affairs, in the United States and Sweden.
In addition to his industry experience, Dr. Carter has a distinguished background in academics. He has served as a Clinical Associate Professor at the University of North Carolina for the Division of Digestive Diseases and Nutrition, School of Medicine, and earlier in his career, Dr. Carter held academic positions with the University of California, where he was responsible for establishing and directing many research programs.
After earning a bachelor's degree in Biochemistry from the University of London, Dr. Carter received his M.D. from the University of Miami and Ph.D. from the University of Cambridge. He obtained board certification from the American Board of Internal Medicine, Gastroenterology and Clinical Nutrition and has authored or co-authored more than 50 scientific publications. Dr. Carter is a member of the American College of Physicians, the American Gastroenterology Association and the American Academy of Pharmaceutical Physicians.
About King Pharmaceuticals
King, headquartered in Bristol, Tennessee, is a vertically integrated branded pharmaceutical company. King, an S&P 500 Index company, seeks to capitalize on opportunities in the pharmaceutical industry through the development, including through in-licensing arrangements and acquisitions, of novel branded prescription pharmaceutical products in attractive markets and the strategic acquisition of branded products that can benefit from focused promotion and marketing and product life-cycle management.
Source: King Pharmaceuticals
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.